SCHEMBL16184476

SCHEMBL16184476

COc1cc(-c2ccccc2F)cc2c(NCCCN(C)C)nc(-c3cccnc3)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.44
▸ USP2 O75604 3/20 0.44
▸ CYP1A2 P05177 3/20 0.44
▸ CYP3A4 P08684 3/20 0.44
▸ CYP2D6 P10635 3/20 0.44
▸ CYP2C9 P11712 3/20 0.44
▸ TSHR P16473 3/20 0.44
▸ CYP2C19 P33261 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ CLK4 Q9HAZ1 3/20 0.44
▸ GBA1 P04062 6/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ RAD52 P43351 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184475 0.95 LMNA (0.44) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184557 0.94 GBA1 (0.41) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184585 0.92 KMT2A (0.42) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184613 0.92 KMT2A (0.42) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184486 0.91 GBA1 (0.52) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184479 0.90 GBA1 (0.48) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184480 0.90 LMNA (0.53) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184530 0.89 POLB (0.46) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184641 0.89 GBA1 (0.44) LMNAUSP2CYP1A2CYP3A4CYP2D6
SCHEMBL16184477 0.89 LMNA (0.46) LMNAUSP2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB LMNA 4832/4885USP2 2663/4885CYP1A2 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback